Research lines 2022-2024

Research lines 2022-2024

LINE 1 – BASIC AND TRANSLATIONAL ONCOLOGY

Study of the molecular, genetic and epigenetic mechanisms at the origin of the resistance of tumors to the main types of systemic treatment, such as molecular target therapy, anti-angiogenic therapy, immunotherapy. The research is conducted both at a pre-clinical level, using appropriate in vitro and murine tumor models, and by analyzing biological samples of patients treated with these drugs. It makes use of multi-omic and inter-disciplinary technological approaches.

LINE 2 – IMMUNOLOGY AND IMMUNOTHERAPY OF TUMORS

This line of activity is focused on analyzing the interactions between immunity and cancer at two levels, systemic and of the neoplastic microenvironment, in particular as regards the development and evolution of the antitumor response, the avoidance mechanisms put in place by the neoplasm and the genetic / metabolic / cellular aspects underlying these events. A further aspect consists in identifying and implementing therapeutic solutions based on the most advanced technologies in the immune field and on the stimulation of the immunoeffective components, with the overall goal of restoring the full efficiency of the immune system and enhancing its anticancer capabilities.

LINE 3 – TRANSLATIONAL CLINICAL RESEARCH AND INNOVATIVE ONCOLOGICAL THERAPIES

A characterizing and priority element of the IOV research is the conduct of innovative clinical studies on precision and translational medicine. Retrospective, observational, translational and interventional studies aimed both at optimizing the treatments already available and at the development of innovative therapies based on molecular characterization and precision medicine are also crucial for producing knowledge on the optimal treatment of patients. Another essential element is the search for predictive and prognostic factors and the use of patient reported outcomes (PROs) that evaluate the impact of new therapies on the quality of life of patients.

LINE 4 – NEW ORGANIZATIONAL MODELS: PDTA AND INDICATORS

The main objective pursued in the drafting of the PDTA of the Veneto Regional Oncological Network (DGR 2067/2013) is to ensure timeliness in taking care of patients, adequate levels of care and continuity of care from the precise moment in which the patient enters the path, to multidisciplinary evaluation, up to the end of life. The definition of PDTAs also provides for the identification of structure, process and outcome indicators which will allow the acquisition of "effectiveness" data of diagnostic, therapeutic and organizational innovations.

Last modified: 31/10/2023 09:29

Scroll to Top